Studying why leukemia stops responding to venetoclax
Collects samples and records from adults with relapsed or refractory chronic lymphocytic leukemia on venetoclax.
Plain-language title generated from the registry record
Registry title: Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Key facts
- Where
- Amiens, Besançon, Bobigny, Clermont-Ferrand, Grenoble, Lille, Lyon, Montpellier, Nancy, Paris, Pessac, Reims, and Toulouse, FranceSee the 14 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic lymphocytic leukemia whose disease came back or stopped responding during or after venetoclax treatment. Samples and medical information are collected to study resistance.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Chronic lymphocytic leukemia diagnosed by iwCLL criteria. The disease came back or did not respond during or after venetoclax. The relapse can be progressive CLL or a change into Richter syndrome.
- Earlier treatment
- Must have had venetoclax treatment. The disease must have relapsed or not responded during or after it.
- Biomarker or test result
- Tumor samples must be available.
Main reasons for not taking part
- Patients or their legal guardians who refuse to take part
- Not affiliated to the French Social Security system
Read by machine on 12 November 2026.
Where in France
- CHU D'amiensAmiens, FranceContact: Lise LaclautreNot yet recruiting
- CHU de BesançonBesançon, FranceContact: Lise LaclautreNot yet recruiting
- Hopital AvicenneBobigny, FranceContact: Lise LaclautreNot yet recruiting
- CHU Clermont-FerrandClermont-Ferrand, FranceContact: Lise LaclautreNot yet recruiting
- CHU de Clermont-FerrandClermont-Ferrand, FranceContact: Lise LaclautreNot yet recruiting
- Chu GrenobleGrenoble, FranceContact: Lise LaclautreNot yet recruiting
- CHRU de LilleLille, FranceContact: Lise LaclautreNot yet recruiting
- Centre Leon BerardLyon, FranceContact: Lise LaclautreNot yet recruiting
- CHU de MontpellierMontpellier, FranceContact: Lise LaclautreNot yet recruiting
- CHU NancyNancy, FranceContact: Lise LaclautreNot yet recruiting
- Hopital Pitie-SalpetriereParis, FranceContact: Lise LaclautreNot yet recruiting
- Hopital Haut-LevequePessac, FranceContact: lise LaclautreNot yet recruiting
- CHU de ReimsReims, FranceContact: Lise LaclautreTaking people
- IUCT OncopôleToulouse, FranceContact: Lise LaclautreNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital, Clermont-Ferrand
- Trial code
- NCT05246345
- Record updated
- 9 January 2024
- Original description
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.Read full original descriptionShow less
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
Inclusion: Age greater than or equal to 18 years old; chronic lymphocytic leukemia diagnosis according to iwCLL criteria; refractory and/or relapsed disease during or after venetoclax treatment; tumor samples available; Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome; Patients must be able to express their opposition to be enrolled in this study, if need be; Patients must be affiliated at the French Social Security system.
Exclusion: Patients of their legal guardians refusing to participate; -.